A long-acting, non-sedating H1-blocking antihistamine used in the treatment of pruritus in dogs and cats.
| Veterinary Dictionary: astemizole |
A long-acting, non-sedating H1-blocking antihistamine used in the treatment of pruritus in dogs and cats.
| 5min Related Video: Astemizole |
| Wikipedia: Astemizole |
| Systematic (IUPAC) name | |
|---|---|
| 1-[(4-fluorophenyl)methyl]- N-[1-[2-(4-methoxyphenyl)ethyl]- 4-piperidyl]benzoimidazol-2-amine | |
| Identifiers | |
| CAS number | 68844-77-9 |
| ATC code | R06AX11 |
| PubChem | 2247 |
| DrugBank | APRD00585 |
| ChemSpider | 2160 |
| Chemical data | |
| Formula | C28H31FN4O |
| Mol. mass | 458.571 |
| SMILES | eMolecules & PubChem |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic |
| Half life | 24 hours |
| Excretion | Fecal |
| Therapeutic considerations | |
| Pregnancy cat. |
C (USA) |
| Legal status |
Unscheduled |
| Routes | Oral |
| |
|
Astemizole (marketed under the brand name Hismanal) is a second generation antihistamine drug which has a long duration of action. Astemizole was discovered by Janssen Pharmaceutica in 1977.
Contents |
It is metabolized by CYP3A4.[1]
It has been withdrawn from the market in most countries because of rare but potentially fatal interactions with CYP3A4 enzyme inhibitors (e.g. erythromycin, grapefruit juice).
Astemizole is an histamine H1-receptor antagonist. It is structurally similar to terfenadine and haloperidol (a butyrophenone antipsychotic). It has anticholinergic and antipruritic effects.
Astemizole competitively binds to histamine H1-receptor sites in the gastrointestinal tract, uterus, blood vessels, and bronchial muscle. This suppresses the formation of edema and pruritus (caused by histamine).
Astemizole does not cross the blood-brain barrier, and H1 receptor binding is mostly in the peripheral rather than central nervous system (CNS depression is thus minimal). Astemizole may also act on histamine H3 receptors, thereby producing adverse effects.
Astemizole is rapidly absorbed from the gastrointestinal tract; protein binding is around 96%.
Astemizole has an oral LD50 of approximately 2052mg/kg (in mice).
It has been reported that this drug might prevent much of the muscle wasting (atrophy) that occurs in immobile, bedridden patients.[2] An experiment on a small number of mice showed that astemizole blocked the activity of a protein present in muscle that is involved in muscle atrophy.[3] However the concerns for the drug's longterm effects on the heart preclude its routine use in humans for this indication.
Astemizole has recently been found to be a potent treatment for malaria. It has a mechanism of action similar to chloroquine but has activity even in chloroquine-resistant parasites.[4]
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
| Astemizole | |
| Erythromycins: Interactions | |
| Erythromycin Lactobionate Solution for injection |
| What are the indications for Astemizole? |
Copyrights:
![]() | Veterinary Dictionary. Saunders Comprehensive Veterinary Dictionary 3rd Edition. Copyright © 2007 by D.C. Blood, V.P. Studdert and C.C. Gay, Elsevier. All rights reserved. Read more | |
![]() | Wikipedia. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article "Astemizole". Read more |